Suppr超能文献

面肩肱型肌营养不良活检的肌肉病理学分级

Muscle pathology grade for facioscapulohumeral muscular dystrophy biopsies.

作者信息

Statland Jeffrey M, Shah Bharati, Henderson Don, Van Der Maarel Silvere, Tapscott Stephen J, Tawil Rabi

机构信息

Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas, USA.

Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA.

出版信息

Muscle Nerve. 2015 Oct;52(4):521-6. doi: 10.1002/mus.24621. Epub 2015 Jun 18.

Abstract

INTRODUCTION

As we move toward planning for clinical trials in facioscapulohumeral muscular dystrophy (FSHD), a better understanding of the clinical relationship with morphological changes in FSHD muscle biopsies will be important for stratifying patients and understanding post-therapeutic changes in muscle.

METHODS

We performed a prospective cross-sectional study of quadriceps muscle biopsies in 74 genetically confirmed FSHD participants (64 with FSHD type 1 and 10 with FSHD type 2). We compared a 12-point muscle pathology grade to genetic mutation, disease severity score, and quantitative myometry.

RESULTS

Pathology grade had moderate correlations with genetic mutation (rho = -0.45, P < 0.001), clinical severity score (rho = 0.53, P < 0.001), disease duration (rho = 0.31, P = 0.03), and quantitative myometry (rho = -0.47, P < 0.001). We found no difference in the frequency of inflammation between FSHD types 1 and 2.

CONCLUSIONS

The pathology grade of quadriceps muscle may be a useful marker of disease activity in FSHD, and it may have a role in stratification for future clinical trials.

摘要

引言

随着我们朝着对面肩肱型肌营养不良症(FSHD)进行临床试验规划迈进,更好地理解FSHD肌肉活检中临床与形态学变化之间的关系对于患者分层以及理解治疗后肌肉变化至关重要。

方法

我们对74名基因确诊的FSHD参与者(64名1型FSHD和10名2型FSHD)的股四头肌活检进行了一项前瞻性横断面研究。我们将12分的肌肉病理学分级与基因突变、疾病严重程度评分和定量肌测量进行了比较。

结果

病理学分级与基因突变(rho = -0.45,P < 0.001)、临床严重程度评分(rho = 0.53,P < 0.001)、疾病持续时间(rho = 0.31,P = 0.03)和定量肌测量(rho = -0.47,P < 0.001)具有中等相关性。我们发现1型和2型FSHD之间的炎症频率没有差异。

结论

股四头肌的病理学分级可能是FSHD疾病活动的一个有用标志物,并且它可能在未来临床试验的分层中发挥作用。

相似文献

1
Muscle pathology grade for facioscapulohumeral muscular dystrophy biopsies.
Muscle Nerve. 2015 Oct;52(4):521-6. doi: 10.1002/mus.24621. Epub 2015 Jun 18.
3
Reduced specific force in patients with mild and severe facioscapulohumeral muscular dystrophy.
Muscle Nerve. 2021 Jan;63(1):60-67. doi: 10.1002/mus.27074. Epub 2020 Oct 15.
4
6
Functional muscle impairment in facioscapulohumeral muscular dystrophy is correlated with oxidative stress and mitochondrial dysfunction.
Free Radic Biol Med. 2012 Sep 1;53(5):1068-79. doi: 10.1016/j.freeradbiomed.2012.06.041. Epub 2012 Jul 11.
7
Milder phenotype in facioscapulohumeral dystrophy with 7-10 residual D4Z4 repeats.
Neurology. 2015 Dec 15;85(24):2147-50. doi: 10.1212/WNL.0000000000002217. Epub 2015 Nov 11.
8
Muscle MRI findings in facioscapulohumeral muscular dystrophy.
Eur Radiol. 2016 Mar;26(3):693-705. doi: 10.1007/s00330-015-3890-1. Epub 2015 Jun 27.
10
MRI as outcome measure in facioscapulohumeral muscular dystrophy: 1-year follow-up of 45 patients.
J Neurol. 2017 Mar;264(3):438-447. doi: 10.1007/s00415-016-8361-3. Epub 2016 Dec 20.

引用本文的文献

1
AAV-shDUX4 provides short-term benefits but limited long-term efficacy in a DUX4 mouse model of FSHD.
Mol Ther Methods Clin Dev. 2025 Jul 12;33(3):101534. doi: 10.1016/j.omtm.2025.101534. eCollection 2025 Sep 11.
2
Estrogen rescues muscle regeneration impaired by DUX4 in a humanized xenograft mouse model.
Cell Death Dis. 2025 Jul 9;16(1):508. doi: 10.1038/s41419-025-07827-2.
4
French National Protocol for diagnosis and care of facioscapulohumeral muscular dystrophy (FSHD).
J Neurol. 2024 Sep;271(9):5778-5803. doi: 10.1007/s00415-024-12538-3. Epub 2024 Jul 2.
5
Muscle eosinophilia is a hallmark of chronic disease in facioscapulohumeral muscular dystrophy.
Hum Mol Genet. 2024 May 4;33(10):872-883. doi: 10.1093/hmg/ddae019.
7
Muscle fibrosis as a prognostic biomarker in facioscapulohumeral muscular dystrophy: a retrospective cohort study.
Acta Neuropathol Commun. 2023 Oct 17;11(1):165. doi: 10.1186/s40478-023-01660-4.
9
Influence of Expression in Facioscapulohumeral Muscular Dystrophy and Possible Treatments.
Int J Mol Sci. 2023 May 30;24(11):9503. doi: 10.3390/ijms24119503.
10
Histopathological correlations and fat replacement imaging patterns in recessive limb-girdle muscular dystrophy type 12.
J Cachexia Sarcopenia Muscle. 2023 Jun;14(3):1468-1481. doi: 10.1002/jcsm.13234. Epub 2023 Apr 20.

本文引用的文献

1
DUX4-induced gene expression is the major molecular signature in FSHD skeletal muscle.
Hum Mol Genet. 2014 Oct 15;23(20):5342-52. doi: 10.1093/hmg/ddu251. Epub 2014 May 26.
2
Restrictive lung involvement in facioscapulohumeral muscular dystrophy.
Muscle Nerve. 2014 Nov;50(5):739-43. doi: 10.1002/mus.24218. Epub 2014 Sep 29.
3
Distinct disease phases in muscles of facioscapulohumeral dystrophy patients identified by MR detected fat infiltration.
PLoS One. 2014 Jan 14;9(1):e85416. doi: 10.1371/journal.pone.0085416. eCollection 2014.
5
Risk of functional impairment in Facioscapulohumeral muscular dystrophy.
Muscle Nerve. 2014 Apr;49(4):520-7. doi: 10.1002/mus.23949. Epub 2014 Feb 10.
7
Different molecular signatures in magnetic resonance imaging-staged facioscapulohumeral muscular dystrophy muscles.
PLoS One. 2012;7(6):e38779. doi: 10.1371/journal.pone.0038779. Epub 2012 Jun 13.
8
The FSHD atrophic myotube phenotype is caused by DUX4 expression.
PLoS One. 2011;6(10):e26820. doi: 10.1371/journal.pone.0026820. Epub 2011 Oct 28.
9
Clinical features of facioscapulohumeral muscular dystrophy 2.
Neurology. 2010 Oct 26;75(17):1548-54. doi: 10.1212/WNL.0b013e3181f96175.
10
A unifying genetic model for facioscapulohumeral muscular dystrophy.
Science. 2010 Sep 24;329(5999):1650-3. doi: 10.1126/science.1189044. Epub 2010 Aug 19.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验